International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 099-105
| Back | Table of Contents | PDF | Mail to Author | |
A 5-Year Multicenter Clinical Experience in Local and Locally Advanced Nasopharyngeal Carcinoma from A Non-Endemic Region: A Retrospective Cohort Study
Ferit ASLAN1, Aysegul ILHAN2, Fatih YILDIZ2, Havva YESIL CINKIR3, Ayca ANT4, Burcin BUDAKOGLU1, BERNA OKSUZOGLU2
1Yüksek Ihtisas University Medicalpark Ankara Batıkent Hospital, Department of Medical Oncology, Ankara, TURKEY
2Health Sciences Unıversity Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Department of Medical Oncology, Ankara, TURKEY
3Gaziantep University,School of Medical, Department Medical Oncology, Gaziantep, TURKEY
4Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital, Department of Head and Neck Surgery, Ankara, TURKEY
Keywords: Nasopharyngeal carcinoma, Survival, Prognosis, Clinical outcomes
Nasopharyngeal carcinoma is an endemic disease in certain geographic regions. This study was undertaken to identify long-term outcome data and prognostic factors for current treatment options in a non-endemic area such as Turkey. One-hundred and thirtytwo patients with local and locally advanced disease treated in three distinct oncology units in Turkey between 2010 and 2019 were retrospectively evaluated. Median duration of follow-up for OS was 68.9 months, respectively. A comparison of adjuvant and induction therapy for locally advanced (Stage 3 and 4a) disease showed a 5-year DFS of 85.5% vs. 76.4%, respectively (p= 0.360). The 5-year OS for adjuvant and induction therapy were 86.4% vs. 91.7, respectively (p=0.569). When factors affecting OS were examined, visceral recurrence was significantly associated with shorter survival (HR: 0.06, 95% CI: 0.014-0.3, p< 0 .001). With regards to DFS, N2-3 status (HR: 2.33, 95% CI: 1.2-6.69, p= 0.017) and stage 3-4a disease (HR: 3.37, 95% CI: 1.01.-11.1, p= 0.047) were associated with earlier recurrence. 5-year OS and DFS outcomes of our patients with nasopharyngeal carcinoma were consistent with the published data. Our results showed that N2-3 disease was a poor prognostic indicator for DFS; on the other hand, visceral metastasis and recurrence were poor prognostic indicators for OS.
Ferit ASLAN1, Aysegul ILHAN2, Fatih YILDIZ2, Havva YESIL CINKIR3, Ayca ANT4, Burcin BUDAKOGLU1, BERNA OKSUZOGLU2
1Yüksek Ihtisas University Medicalpark Ankara Batıkent Hospital, Department of Medical Oncology, Ankara, TURKEY
2Health Sciences Unıversity Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Department of Medical Oncology, Ankara, TURKEY
3Gaziantep University,School of Medical, Department Medical Oncology, Gaziantep, TURKEY
4Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital, Department of Head and Neck Surgery, Ankara, TURKEY
Keywords: Nasopharyngeal carcinoma, Survival, Prognosis, Clinical outcomes
Nasopharyngeal carcinoma is an endemic disease in certain geographic regions. This study was undertaken to identify long-term outcome data and prognostic factors for current treatment options in a non-endemic area such as Turkey. One-hundred and thirtytwo patients with local and locally advanced disease treated in three distinct oncology units in Turkey between 2010 and 2019 were retrospectively evaluated. Median duration of follow-up for OS was 68.9 months, respectively. A comparison of adjuvant and induction therapy for locally advanced (Stage 3 and 4a) disease showed a 5-year DFS of 85.5% vs. 76.4%, respectively (p= 0.360). The 5-year OS for adjuvant and induction therapy were 86.4% vs. 91.7, respectively (p=0.569). When factors affecting OS were examined, visceral recurrence was significantly associated with shorter survival (HR: 0.06, 95% CI: 0.014-0.3, p< 0 .001). With regards to DFS, N2-3 status (HR: 2.33, 95% CI: 1.2-6.69, p= 0.017) and stage 3-4a disease (HR: 3.37, 95% CI: 1.01.-11.1, p= 0.047) were associated with earlier recurrence. 5-year OS and DFS outcomes of our patients with nasopharyngeal carcinoma were consistent with the published data. Our results showed that N2-3 disease was a poor prognostic indicator for DFS; on the other hand, visceral metastasis and recurrence were poor prognostic indicators for OS.
| Back | Table of Contents | PDF | Mail to Author | |